| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514154000 | With an additional active ingredient (excludes reaction product or complex) | 69 |
| 20080287402 | Use of a glial attenuator to prevent amplified pain responses caused by glial priming - The use of a glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), to prevent the negative consequences of glial priming is described. In particular, the present invention is directed to a method of treating a subject with ibudilast to prevent amplified pain responses to inflammation or injury as a result of glial priming following an initial glial activating event. | 11-20-2008 |
| 20080293680 | Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II - The invention relates to a compound of the formula (I), wherein R | 11-27-2008 |
| 20090036411 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES - Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions. | 02-05-2009 |
| 20090163448 | Diagnosis and treatment of human dormancy-related sequellae - New methods for diagnosis and treatment of human dormancy syndrome-related sequellae are provided. Human dormancy syndrome (HDS) is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects. HDS includes fibromyalgia, chronic fatigue, cancer, autoimmune disease, obesity and related dormancy conditions. Dormancy and HDS-related sequellae are imposed on humans by infection with lipopolysaccharide (LPS; or endotoxin)-producing organisms, especially those that are intracellular and those that create antigens that stimulate the TLR pathways. In such instances, the elimination or neutralization of the LPS signal along with the infectious source is required to impact the sequellae of HDS. Treatment includes use of novel and non-obvious doses of antibiotics, optionally including agents that decrease the adverse effects of endotoxin. | 06-25-2009 |
| 20090176747 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT - The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders. | 07-09-2009 |
| 20090209497 | METHOD OF TREATING LYMPHANGIOLEIOMYOMATOSIS (LAM) - The invention provides a method for the treatment of Lymphangioleiomyomatosis (LAM) in the human subject in need thereof. The method comprises administering to the subject an effective amount of doxycycline or a salt thereof. The invention further provides a method for monitoring the efficacy of treatment. Treatment efficacy is monitored by measuring MMP levels. Reduction in MMP levels indicates that the treatment is effective. | 08-20-2009 |
| 20090209498 | Methods of Treatment Using CCA1 Inhibitors - Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor. | 08-20-2009 |
| 20090221533 | METHOD OF TREATING FATTY LIVER DISEASE - The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor. | 09-03-2009 |
| 20090253661 | OCULAR AGENTS - A method to reduce or ameliorate an ocular condition, such as ocular scarring that may occur after ocular surgery or another non-surgical ocular inflammatory or other condition, by topically administering doxycycline as the sole active agent to a patient in need thereof under conditions to reduce or ameliorate the ocular condition. | 10-08-2009 |
| 20090325909 | Suppression of HIV replication and prevention and treatment of HIV - The invention provides a new and effective treatment for human immunodeficiency diseases, particularly for HIV-infected individuals. The treatment utilizes tetracycline analogs, particularly minocycline, in amounts that are effective to prevent HIV replication both the central nervous system and in peripheral blood. | 12-31-2009 |
| 20100029597 | RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE - The present invention is directed to the use of RecA inhibitors as antibiotic agents, and provides RecA inhibitors useful in treating infections. Also provided are various compositions and methods associated with RecA inhibition. | 02-04-2010 |
| 20100130452 | Use of Doxycycline in the Treatment of Idiopathic Pulmonary Fibrosis - Use of doxycycline, a non specific matrix metalloproteinase inhibitor, for treatment of idiopathic pulmonary fibrosis and a pharmaceutical composition comprising doxycycline or its congener in combination with another compound selected from the drug listed for treatment of idiopathic pulmonary fibrosis in a standard dose. | 05-27-2010 |
| 20100144681 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to substituted 1,2-ethylenediamines of general formula (I), | 06-10-2010 |
| 20100168070 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to substituted 1,2-ethylenediamines of general formula (I), | 07-01-2010 |
| 20100197640 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT - The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia. | 08-05-2010 |
| 20100240619 | FUNGICIDAL MIXTURES - Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, | 09-23-2010 |
| 20100298278 | INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to the substituted 1,2-ethylenediamines of general formula (I), | 11-25-2010 |
| 20100317629 | DISSOLVABLE PHARMACEUTICAL IMPLANT - A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device. | 12-16-2010 |
| 20110003776 | TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF - This invention relates to tetrahydropyranonaphthyridines derivatives having formula (III) or IV: | 01-06-2011 |
| 20110021466 | USE OF EPICATECHIN AND DERIVATIVES AND SALTS THEREOF FOR CARDIAC PROTECTION OF ISCHEMIC MYOCARDIUM AND TO AMELIORATE ADVERSE CARDIAC REMODELING - The disclosure provides a method of reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof, wherein the subject is a human or a veterinary animal. Additionally the disclosure provides a method of treating subarachnoid hemorrhage or atrial fibrillation or of enhancing or preserving migration, seeding, proliferation, differentiation and/or survival of stem cells in injured heart tissue comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof. The effects of epicatechin administration are sustained over time. | 01-27-2011 |
| 20110039806 | COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The present invention provides combinations of an antipsychotic drug and a tetracycline, particularly minocycline, for the treatment of psychotic disorders, particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the combined therapy for treatment of psychotic disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline. | 02-17-2011 |
| 20110059925 | METHODS FOR IMPROVING LID MARGIN AND TEAR FILM FUNCTION AND TREATMENT OF LID MARGIN DISEASE USING TETRACYCLINE FAMILY ANTIBIOTICS - The present invention provides a mucoadhesive broad spectrum antibiotic with anti-inflammatory characteristics with strong tissue penetration for improving lid margin function and the treatment of diseases associated therewith. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of blepharitis and dry eye disease. | 03-10-2011 |
| 20110098255 | COMBINATION OF A PARP INHIBITOR AND AN AKT KINASE ACTIVATING COMPOUND - The primary subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination in the treatment of pathological conditions related to PARP activation and/or that could benefit from Akt activation. A further subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination for the preparation of pharmaceutical composition or kit for the treatment of a pathological condition related to PARP activation. The invention also relates to pharmaceutical composition, which contains a PARP-inhibitor and an Akt kinase activating compound together with auxiliaries generally used in pharmacy. | 04-28-2011 |
| 20110183943 | CONCURRENT THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE RELATED DISEASES - A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy. | 07-28-2011 |
| 20110269720 | MINOCYCLINE AND RIFAMPIN MICROPARTICLES - Methods and kits for treating infection associated with implantation of a medical device use of minocycline and rifampin microparticles. The microparticles, in a suitable medium, can be injected in a patient in proximity to the device. The drugs may be configured to be released from the polymer matrix in a controlled manner by manipulation of the properties of the polymer forming the microparticle. By injecting the drugs in the form of microparticles, the drugs can be distributed in a manner so that the entire pocket is protected without affecting device function. The microparticles can be produced aseptically without affecting the manufacturing of the device. | 11-03-2011 |
| 20110288056 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 11-24-2011 |
| 20110294760 | Compositions and Methods for Preventing Sternal Wound Infections - The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be topically applied to an esophageal perforation in a subject or a median sternotomy incision site in the subject, and in which the at least one antimicrobial agent is present in an amount effective to inhibit development of mediastinitis in the subject. | 12-01-2011 |
| 20110301127 | METHODS OF REDUCING MICROBIAL RESISTANCE TO DRUGS - The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity of drugs are provided. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided. | 12-08-2011 |
| 20120101071 | SubstitutedTetracycline Compounds for the Treatment of Malaria - This invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compositions which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compounds of the invention can be used to in combination with one or more anti-malarial compounds or can be used to treat or prevent malaria which is resistant to one or more other anti-malarial compounds. | 04-26-2012 |
| 20120115820 | ACID PUMP ANTAGONIST FOR THE TREATMENT OF DISEASES INVOLVED IN ABNORMAL GASTROINTESTINAL MOTILITY - The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases. | 05-10-2012 |
| 20120129816 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS - The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them. | 05-24-2012 |
| 20120232040 | MEDICATION FOR CLINICAL EXTENSIVELY-DRUG RESISTANT ACINETOBACTER BAUMANNII - A medication for | 09-13-2012 |
| 20120258937 | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis - Methods for inhibiting estrogen hormone-induced pulmonary metastasis of smooth muscle cells that are capable of pulmonary metastasis comprise antagonizing the estradiol receptor on the smooth muscle cells such that pulmonary metastasis of the cells is inhibited. | 10-11-2012 |
| 20120270844 | METHODS FOR TREATING ALZHEIMER'S DISEASE - Provided herein arc PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from Alzheimer's disease. | 10-25-2012 |
| 20120283225 | Combination Therapy for Skin Disorders - The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder. | 11-08-2012 |
| 20120302526 | METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER - Provided herein are methods for treating negative effects of traumatic brain injury (TBI), post traumatic stress disorder (PTSD), or acute stress disorder (ASD). These methods comprise administration of an effective amount of ibudilast to a subject suffering from TBI, PTSD, or ASD. | 11-29-2012 |
| 20120302527 | C7-Fluoro Substituted Tetracycline Compounds - The present invention is directed to a compound represented by Structural Formula (A): | 11-29-2012 |
| 20130059824 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT - Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from Mild Cognitive Impairment. | 03-07-2013 |
| 20130102572 | METHODS OF TREATING SKIN CONDITIONS EXHIBITING TELANGIECTASIA - The present application relates to methods of preventing or treating skin disorders exhibiting telangiectasia, for example, rosacea exhibiting an erythematotelangiectatic subtype. Exemplary methods comprise administering to a patient a formulation comprising a therapeutically effective amount of an mTOR inhibitor, such as rapamycin, wherein the mTOR inhibitor is the only active agent in the formulation. Suitably, the formulations are topical formulations administered to the face. | 04-25-2013 |
| 20130109657 | C7-Fluoro Substituted Tetracycline Compounds | 05-02-2013 |
| 20130123217 | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS - The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10. | 05-16-2013 |
| 20130172298 | Okadaella Gastrococcus and Cancer - The present invention provides compositions, methods of manufacture, process and uses for diagnosing, preventing, inhibiting, and treating the development and proliferation of diseases and disorders associated with | 07-04-2013 |
| 20130190275 | COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The present invention provides combinations of an antipsychotic drug and a tetracycline, particularly minocycline, for the treatment of psychotic disorders, particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the combined therapy for treatment of psychotic disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline. | 07-25-2013 |
| 20130310345 | Use of TRPA1 Antagonists to Prevent or Treat Infections Caused by Biological-Warfare Agents - Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I | 11-21-2013 |
| 20130310346 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS WITH IRON CHELATORS - The present invention provides methods and compositions for treating or preventing bacterial infections, where a pharmaceutically acceptable iron chelator that reduces biological availability of iron for one or more strains of bacteria, such as VK28 or an analog or derivative thereof is administered to a patient in need of treatment. The method also provides methods and compositions where an iron chelator and an antibiotic are administered to a patient in need of treatment for a bacterial infection. | 11-21-2013 |
| 20130324500 | SPINAL CORD INJURY, INFLAMMATION AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS - A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury. | 12-05-2013 |
| 20130338118 | COMPOUNDS FOR TREATMENT OF HEART FAILURE - A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated. | 12-19-2013 |
| 20140018324 | METHOD FOR IMPROVING TETRACYCLINE-RESISTANCE OF ACINETOBACTER BAUMANNII - A method for improving tetracycline-resistance of | 01-16-2014 |
| 20140100201 | CONNECTIVE TISSUE MONITORING, COMPOSITIONS FOR CONNECTIVE TISSUE TREATMENT AND METHODS FOR TREATING CONNECTIVE TISSUE - Methods and computer instruction code for monitoring, screening and classifying the response to load of a connective tissue or part thereof are disclosed. The method includes the steps of obtaining or receiving an ultrasound scan of a connective tissue or part thereof and analysing the ultrasound scan to detect one or more region of differential structural disorganisation in the connective tissue or part thereof. The connective tissue or part thereof is then classified according to the detected one or more region of differential structural organisation to thereby monitor the response to load of the connective tissue or part thereof. Also disclosed are compositions and methods of treatment for a connective tissue disease or condition. | 04-10-2014 |
| 20140128351 | COMBINATION THERAPY FOR SKIN DISORDERS - The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder. | 05-08-2014 |
| 20140135296 | METHODS OF TREATING AUTOPHAGY-ASSOCIATED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS - The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels. | 05-15-2014 |
| 20140179639 | MELOXICAM FOR THE TREATMENT OF RESPIRATORY DISEASES IN PIGS - A method of treating or preventing a respiratory disease in a pig is described that includes administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof. | 06-26-2014 |
| 20140235593 | SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARB- OXAMIDES FOR ANTIMALARIAL THERAPIES - In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating and/or preventing malaria. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 08-21-2014 |
| 20140274972 | Compositions and Methods employing Wolbachia FtsZ as a target for Albendazole sulfone - Compositions and Methods are described in which Albendazole sulfone binds to | 09-18-2014 |
| 20140296188 | NEW THERAPY FOR TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS - It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate. | 10-02-2014 |
| 20140323443 | TIGECYCLINE FORMULATIONS - A tigecycline composition includes tigecycline and arginine, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, tigecycline and arginine, and lyophilizing the liquid mixture. | 10-30-2014 |
| 20140329777 | METHODS TO TREAT INFECTIONS - Methods to treat infectious diseases are disclosed herein. Some embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) to treat infectious diseases. Other embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) and administration of one or more antibiotics to treat infectious diseases. | 11-06-2014 |
| 20150141380 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY - A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof. | 05-21-2015 |
| 20150141381 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES - Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described. | 05-21-2015 |
| 20150290361 | Small molecule drug release from in situ forming degradable scaffolds incorporating hydrogels and bioceramic microparticles - The present invention relates to an injectable system combining a hydrogel, a bioceramic and a degradable matrix that provides for sustained drug delivery and structural support to recovering tissue, such as bone and the periodontium. | 10-15-2015 |
| 20150359791 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES - The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens. | 12-17-2015 |
| 20160030452 | Minocycline Derivatives - This invention relates generally to minocycline derivatives, and to compositions, including pharmaceutical compositions, containing such minocycline derivatives. The invention also relates to methods of synthesizing minocycline derivatives and to methods for using such minocycline derivatives as anti-bacterial agents for treating or preventing infections. | 02-04-2016 |
| 20160030566 | TREATMENT OF MULTIPLE SCLEROSIS - A composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. A method of treating neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and treating neurodegeneration. A method of reducing and/or eliminating symptoms of neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and reducing and/or eliminating the individual's symptoms of neurodegeneration. A method of reducing and/or eliminating lesions from neurodegeneration. A method of recovering mobility of an individual suffering from neurodegeneration. | 02-04-2016 |
| 20160045499 | MINOXIDIL FOR SUPPRESSING ANDROGEN RECEPTOR FUNCTION - Methods for treating androgen receptor related diseases and suppressing androgen receptor related function by administering an effective amount of minoxidil are provided. Methods for treating or prophylactically treating acne by administering an effective amount of minoxidil are also provided. An anti-acne medication is optionally administered to treat or prophylactically treat acne. | 02-18-2016 |
| 20160045520 | USE IN ONE PILL TABLET CAPSULE MINOCYCLINE ACYCLOGUANOSINE ATORVASTATIN AND VITAMIN D3 IN THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention has for object the use of minocycline or its equivalent forms, or any form of tetracycline in combination with acycloguanosine or any equivalent form (antiviral), atorvastatin or any equivalent form (lipophilic statins) and vitamin D3 (pro hormone) for the preparation of a single compound addressed to treatment of autoimmune type of rheumatoid arthritis in the three stages of development, whether it is active or quiescent phase or forms of diseases eziopatologicamente equivalent, but some degenerative. The efficacy of this combination has been proven by many studies on individual components. To date, given the proven effectiveness of the individual components, the low toxicity of the same and the long period of their marketing, as well as the observed higher efficiency of the combination of these used in accordance with the new mode overexposed, it can be said that the new compound abovementioned derived from a combination of minocycline or its equivalent forms, or any form of tetracycline in combination with acycloguanosine or any equivalent form (antiviral), atorvastatin or any equivalent form (lipophilic statins) and vitamin D3 (pro-hormone), is effective in reducing the incidence of the disease on quality of life of the patient, in particular with a certain dose level, before today never identified or determined. | 02-18-2016 |
| 20160051570 | TREATMENT OF RHEUMATOID ARTHRITIS - A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and treating chronic inflammation. A method of reducing and/or eliminating symptoms of chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and reducing and/or eliminating the individual's symptoms of chronic inflammation. | 02-25-2016 |
| 20160151333 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | 06-02-2016 |
| 20160194286 | NEW ANTI-MALARIAL AGENTS | 07-07-2016 |
| 20170232008 | MULTI-INGREDIENT PHARMACEUTICAL COMPOSITION FOR USE IN CANCER THERAPY | 08-17-2017 |
